Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 6, 2008, Pages 1718-1725

  Fishbane, Steven ^a   Shapiro, Warren B ^b   Corry, Dalila B ^c   Vicks, Steven L ^d   Roppolo, Michael ^e   Rappaport, Kenneth ^f   Ling, Xiang ^g   Goodman, William G ^g   Turner, Stewart ^g   Charytan, Chaim ^h  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^c OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^d Sparks Dialysis ^*  (United States)

^e Renal Associates of Baton Rouge   (United States)

^f Palm Beach Gardens Medical Center   (United States)

^g AMGEN INC   (United States)

^h NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; NAPHTHALENE DERIVATIVE; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN; VITAMIN D;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HUMAN; KIDNEY DISEASE; MALE; METABOLISM; MIDDLE AGED; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM; TIME; TREATMENT OUTCOME;

ADULT; AGED; CALCIUM; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D; VITAMINS;

EID: 58149334973     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01040308     Document Type: Article

References (29)

1. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl]: S1-S201, 2003
2. Dressler R, Laut J, Lynn RI, Ginsberg N: Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol 43: 324-331, 1995
3. Gonella M, Calabrese G, Aleo AG, Vagelli G, Deambroglo P: Calcitriol pulse therapy for severe hyperparathyroidism or calcium salts as phosphate binders in renal dialysis patients. Nephron 71: 350-353, 1995
4. Wallot M, Bonzel KE, Winter A, Geörger B, Lettgen B, Bald M: Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol 10: 625-630, 1996
5. Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E: Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant 11[Suppl 3]: 121-124, 1996
6. Tan AU Jr, Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC, Kleinman KS, Coburn JW: Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51: 317-323, 1997
7. Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y: Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 32: 238-246, 1998
8. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63: 1483-1490, 2003
9. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y: Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 35: 458-464, 2000
10. Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9: 1427-1432, 1998
11. Frazão JM, Chesney RW, Coburn JW: Intermittent oral 1αhydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Transplant 13[Suppl 3]: 68-72, 1998
12. Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Intermittent doxercalciferol (1α-hydroxyvitamin D2) therapy for secondary hyperparathyroidism. Am J Kidney Dis 36: 550-561, 2000
13. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Ohashi Y, Ogata E, Slatopolsky E, Kurokawa K: Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients: one-year administration study. Nephrol Dial Transplant 17[Suppl 10]: 28-36, 2002
14. Llach F, Yudd M: Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38[Suppl 5]: S45-S50, 2001
15. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
16. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021, 2000
17. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
18. Ureña P, Malergue MC, Goldfarb B, Prieur P, Guédon-Rapoud C, Pétrover M: Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrologie 20: 217-225, 1999
19. Marchais SJ, Metivier F, Guerin AP, London GM: Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 14: 2178-2183, 1999
20. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35: 1226-1237, 2000
21. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106: 100-105, 2002
22. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695-701, 2002
23. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638-647, 2002
24. Maung HM, Elangovan L, Frazao JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 37: 532-543, 2001
25. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003
26. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR: Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65: 1914-1926, 2004
27. Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM: Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 28: 97-106, 2008
28. Martin KJ, Akhtar I, Gonzalez EA: Parathyroid hormone: new assays, new receptors. Semin Nephrol 24: 3-9, 2004
29. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GFM: Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147: 840-853, 2007